Some venture capital firms are striking deals claiming a percentage of royalties, as Aisling Capital and Clarus Ventures recently did with Pharmacyclics' tyrosine kinase inhibitor ibrutinib. "[T]he royalty play illustrates the 'new normal' in life sciences VC investing: a search for investments with short time horizons; a lack of faith in preclinical or even phase I molecules and the teams developing them; and an irresistible pull to 'sure-fire' deals of a more financial nature," writes CBT Advisors CEO Steve Dickman.
Biotech venture capitalists take the royalties route
SmartBrief Job Listings for Health Care
|Sr. Regulatory Specialist, Biotech Center of Expertise||
BASF, The Chemical Co.
|San Diego, CA|
|Director of Clinical Research||
Regenesis Biomedical, Inc.
Meridian Health Plan
|Assistant Vice President - Dental Director||